Resveratrol improves rapamycin strength
A recent study conducted at the Cleveland Clinic by the Lerner Research Institute has confirmed that the antioxidant power of resveratrol, found in supplements like Transmax and Bioforte can increase the potency of some anti-cancer drugs by preventing cancer cells from building up a resistance to some drugs like Rapamycin
Dr Charis Eng, who led the study at the Cleveland Clinic, said: “Our findings show that resveratrol seems to mitigate rapamycin-induced drug resistance in breast cancers, at least in the laboratory.
If these observations hold true in the clinic setting, then enjoying a glass of red wine or eating a bowl of boiled peanuts – which has a higher resveratrol content than red wine – before Rapamycin treatment for cancer might be a prudent approach.”
For the study, the cancer treatment drug Rapamycin was focused on as cancer cells are known to build up a level of resistance to this drug over time. Rapamycin is an immuno-suppressant which can also slow the growth of cancerous tumours, stop them or make them smaller.
Dr Charis Eng added that: “The lab study on human breast cancer cell lines found that when Rapamycin was used in conjunction with resveratrol, it was twice as effective at killing those cells than using Rapamycin alone.”
Resveratrol is being touted by some researchers as a possible anti-aging compound. Resveratrol can be found in fruits such as berries and grapes, as well as in peanuts. It is a naturally occurring phytoalexin that plants produce in response to threats from fungus or pathogens.
Other recent studies have shown resveratrol has had a beneficial effect for diseases and conditions, such as cardio-vascular disease, macular-degeneration and cognitive function. The possible anti-bacterial and anti-inflammatory properties of resveratrol are also being researched.
A spokesperson for resveratrol manufacturer, Biotivia, said: “This is just the latest in a long line of studies being conducted on resveratrol’s health benefits and highlights another application towards human health. We recently collaborated in a study with the Albert Einstein Medical Center into insulin resistance, a pre-cursor to diabetes, with very positive results using our resveratrol supplement, Transmax. Our Bioforte supplement was shown to increase brain blood flow by up to 200% in a study done by Northumbria University in the UK.
Transmax is the only 500mg resveratrol supplement to be approved in recently released 2010 ConsumerLab resveratrol brand evaluations. Transmax is the highest potency independently tested resveratrol supplement containing pure trans-resveratrol with no inert additives or fillers of any type. Transmax resveratrol has also been used in virtually all of the human clinical trials carried out over the past five years.
Transmax has also been fortified with pure Polydatin, a rare and highly bio active analog of resveratrol which more than doubles resveratrol’s half life in cells and tissues, bio-availability and its antioxidant power.
The Biotivia spokesperson continued: “Our products are the purest, highest-potency, best value and freshest quality-validated Resveratrol supplements available anywhere. With Transmax you will actually feel more energy, reduced appetite and cravings, better sleep and lower Blood Sugar. We guarantee it.”
To read more about Transmax visit http://www.biotivia.com/transmaxresveratrol.html
About Biotivia LLC
Biotivia was established in 1992 in Vienna, Austria as a supplier of natural raw materials and biologically active botanics to the supplement and functional food industries and to researchers and scientific institutions worldwide. The company evolved into one of the world’s leading developers and suppliers of unique science-based nutritional supplements and award winning skin care therapies, with most of their products centered around the use of concentrated resveratrol and complementary botanical extracts.
Biotivia presently has US offices in New York, Los Angeles, Kansas City and international offices in the UK, Spain, Austria, Denmark, Italy, Germany, Singapore, Xi’an, China and Mumbai, India.
Beyond its strong consumer base, the company currently supplies researchers, physicians and scientists at Harvard, Stanford, Yale, Georgetown, The Albert Einstein Medical Center, University of Texas, M.D. Anderson Cancer Center, Health Canada, and the University of California. Transmax and Bioforte in particular are being investigated by several major university medical schools as a possible treatment for a variety of conditions that seriously impair the health and well being of millions of people around the world. Biotivia most recently signed an agreement to supply Transmax to the University of Ferrara for use in three human clinical trials in Italy and Egypt on its possible use by Thalassemia sufferers as an alternative to the whole blood transfusions which such patients now require monthly. The Albert Einstein Medical College published a study which elucidated the beneficial effects of Biotivia’s proprietary resveratrol on glucose tolerance and mitochondria function in pre-diabetic subjects. Bioforte was also shown to more than double brain blood flow in a study done at the University of Northumbria in the UK.
Biotivia’s resveratrol products, Transmax and Bioforte, have been independently assessed by Consumer Labs, the leading American quality watchdog, and were deemed both ‘most potent’ and ‘best value’. Transmax has been certified as an investigational drug by the NIH, an endorsement of its safety and purity.
Most of Biotivia’s supplements have been certified Vegan by the American Vegetarian Association.
Important Caveat: Neither Transmax nor any Biotivia product has been definitively shown to diagnose, prevent or cure any age related diseases. Transmax is not intended to diagnose, prevent, treat or cure any disease. Studies done in vitro and on animals do not always translate into the same biological effect when taken by human subjects. The statements herein have not been reviewed or approved by the US FDA. All Biotivia supplements are manufactured in state of the art government inspected pharmaceutical facilities in accordance with CGMP and USP standards.
Other press releases from Biotivia Bioceuticals LLC
- Anti-diabetic potential of resveratrol shown in study - September 2nd, 2011
- Biotivia Launch New Pterostilbene Supplement Called PteroActiv - August 23rd, 2011
- Resveratrol Could Benefit Type 2 Diabetics - August 23rd, 2011
- PteroActiv, the new pterostilbene supplement from Biotivia - August 16th, 2011
- Bowel Disorders Can Be Eased With Probiotic Supplements - August 16th, 2011
Contact InformationLeo Day
Title: Marketing Consultant
Biotivia Bioceuticals LLC